QPS will have a strong presence at ASCPT 2016 in San Diego March 9th-11th. Several members of QPS’ Early Phase Clinical team will be representing QPS’ 500 phase I clinical beds and full service clinical research services. Please stop by and visit QPS at Booth #4 at ASCPT, Hilton Bayfront San Diego, CA, USA while …
QPS is proud to announce that our toxicology facility passed a GLP audit by the US FDA in 3Q 2015 with no major findings.
We are exhibiting at SOT 55th Annual Meeting and ToxExpoTM. Please visit our booth (#1813) between March 13-16 at the New Orleans Convention Center, New Orleans, LA, USA.
QPS Global Clinical Operations Team Aces Enrollment for Global Study of Prostate Cancer Drug and Completes the First Patient in Europe!
QPS has been assisting an international Sponsor to perform a global, late-phase study to investigate the safety, efficacy, and pharmacokinetic behavior of a newly formulated investigational drug in subjects with advanced prostate carcinoma. The original enrollment goal was 133 patients to be enrolled in approximately 18 months. The QPS Global Clinical Operations team enrolled 137 …
QPS will create an (LC)-ICP-MS assay to perform the critical elemental analysis in your drug development study
If you need to quantify blood zinc levels, are working on a gadolinium-based MRI contrast agent, or need to measure platinum levels in mouse livers – a QPS-developed (LC)-ICP-MS assay may well be what you need. These assays, validated according to FDA, EMA and ICH guidelines, can quantify levels of most ELEMENTS (such as iron, …
QPS Seen As Inspirational for Delaware
Where do you turn when you just took the package? 25% of DuPont employees (likely more on the way) got the bad news here in Delaware, USA when DuPont merged with Dow Chemical in December. The state is hoping to stem the brain (and $) drain by encouraging these people to consider starting up new …
Consultation open on revised EMA Guideline on Medicines to treat Alzheimer’s Disease
The European Medicines Agency (EMA) has released a draft guideline revision on the clinical investigation of medicines for the treatment of Alzheimer’s disease and other dementias for a six-month public consultation. The EMA considers dementia a key public health priority and sees early stage intervention and prevention of symptomatic disease as particularly worthy goals. This …
New ICP-MS Magnesium (Mg) Assays in Human Plasma and Urine added to the QPS Global Assay Database
The role of Mg in human nutrition has recently received renewed interest. Mg dietary intake has been reported to have decreased during the last 100 years in Western countries. For example, in the US it is often below the recommended dietary allowances. Decreased Mg intake and/or low serum Mg have been associated with a number …
See QPS in London at Informa’s Early Clinical Development Conference, 23 – 24 February 2016
On February 23, Professor Zuzana Diamant, MD PhD, Director of Respiratory & Allergy Research at QPS, will talk about Biomarkers in Respiratory Drug Development and personalized medicine at the Informa-sponsored Early Clinical Development conference, Amba Hotel Marble Arch, London. In her lecture, Professor Diamant will cover the following topics: Definition of a valuable biomarker Which …
Read the QPS Whitepaper on Phase I Site Selection to support EU Registration
Making the right decision about where to conduct Phase I of a clinical trial is crucial. As long as basic EU regulatory requirements are fulfilled, the investigational site may be located anywhere in the world. This paper will walk you through the three key essential considerations for clinical trials intended to support registration in the …
Wishing You a Very Happy New Year, With Some Very Cool Science
Cancer immuno therapies. Oligo therapeutics. CAR T-cell therapies. Breakthrough Antivirals. For the past 20 years, we’ve been following the path of solid science and it’s lead us to this point: about to close out another year spent partnering with the world’s best pharmaceutical and biotech companies in pursuit of better solutions for patients. As our …
